Michael Breen's Insider Trades & SAST Disclosures

Michael Breen's most recent trade in GT Biopharma Inc was a trade of 100,000 Option to purchase Common Stock done . Disclosure was reported to the exchange on Sept. 4, 2025.

Share

Note

This is a custom search result for pattern Michael Breen.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.

All Superstars

"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches "Balanced Fund" but not "Balanced Growth Fund" Balanced Fund: Use this format without quotation marks to search for all funds related to the term "Balanced Fund" The results may include "Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".

Stock	Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
GT Biopharma Inc	Michael Breen	Director, CEO and Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Sep 2025	100,000	100,000	-		-	Option to purchase Common Stock
GT Biopharma Inc	Michael Breen	Director, CEO and Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Sep 2025	100,000	100,000	-		-	Option to purchase Common Stock
GT Biopharma Inc	Michael Breen	Director, CEO and Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Sep 2025	100,000	100,000	-		-	Option to purchase Common Stock
GT Biopharma Inc	Michael Breen	Director, Executive Chairman/Interim CEO	Grant, award, or other acquisition of securities at price $ 0.29 per share.	11 Aug 2023	200,000	856,218	-	0.3	57,400	Common Stock
GT Biopharma Inc	Michael Breen	Director, Executive Chairman/Interim CEO	Purchase of securities on an exchange or from another person at price $ 0.50 per share.	11 Apr 2023	50,000	656,218	-	0.5	25,000	Common Stock
GT Biopharma Inc	Michael Breen	Director, Exec Chairman and Interim CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	27 Jan 2023	500,000	500,000	-		-	Option to purchase Common Stock
GT Biopharma Inc	Michael Breen	Director, Exec. Chair. and Interim CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jul 2022	278,058	606,218	-		0	Common Stock
GT Biopharma Inc	Michael Breen	Director, Exec. Chair. and Interim CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jul 2022	50,000	50,000	-		-	Option to purchase Common Stock

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades